In the News May 22, 2017

The Pink Sheet | US FDA Urged To Rethink Warning Letters To Avoid 'Collateral Damage'

Cathy Burgess is quoted about the impact that warning letters from the U.S. Food and Drug Administration can have on a manufacturer's operations and reputation.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.